Health Economics›Gastric cancer›Metastatic or locally advanced disease subsequent lines of therapy

Metastatic or locally advanced disease subsequent lines of therapy

Gastric cancer · 22 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy · 10 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Trifluridine and tipiracil monotherapy Variant #01	—	R 1 067 070	28d	—	5.7 mo	2	R 2 134 140 PFS proxy	1
Pembrolizumab monotherapy Variant #01	—	R 286 955	14d	—	9.1 mo	2	R 573 911 PFS proxy	1
Regorafenib monotherapy Variant #01	—	R 132 655	28d	2.6 mo	4.5 mo	2	R 265 310 PFS proxy	2
Paclitaxel and Ramucirumab Variant #01	—	R 98 182	28d	4.1 mo	10.5 mo	2	R 196 364 PFS proxy	3
Paclitaxel and Ramucirumab Variant #01	ERBB2	R 98 182	28d	4.1 mo	10.5 mo	2	R 196 364 PFS proxy	3
Trastuzumab deruxtecan monotherapy Variant #01	ERBB2	R 81 019	21d	—	13.6 mo	2	R 162 039 PFS proxy	2
Ramucirumab monotherapy Variant #01	—	R 48 173	14d	—	5.2 mo	2	R 96 346 PFS proxy	1
nab-Paclitaxel monotherapy Variant #01	—	R 16 043	28d	—	11.1 mo	2	R 32 087 PFS proxy	1
Fluorouracil, Folinic acid, Mitomycin Variant #01	—	R 12 524	56d	—	—	~2	~R 25 048 indirect	—
Docetaxel monotherapy Variant #02	ERBB2	R 2 921	28d	1.8 mo	5.3 mo	10	R 29 215 PFS proxy	4
Docetaxel monotherapy Variant #02	—	R 2 921	28d	1.8 mo	5.3 mo	10	R 29 215 PFS proxy	4
Irinotecan monotherapy Variant #01	ERBB2	R 2 716	42d	2.3 mo	8.4 mo	11	R 29 874 PFS proxy	9
Irinotecan monotherapy Variant #01	—	R 2 716	42d	2.3 mo	8.4 mo	11	R 29 874 PFS proxy	9
Irinotecan and Mitomycin Variant #01	—	R 2 040	28d	—	—	~7	~R 14 280 indirect	—
Paclitaxel and Fruquitinib Variant #01 Partial	—	R 1 836	28d	5.6 mo	9.6 mo	7	R 11 016 PFS proxy	2
Paclitaxel monotherapy Variant #02	ERBB2	R 734	28d	2.9 mo	8.3 mo	7	R 5 141 PFS proxy	17
Paclitaxel monotherapy Variant #02	—	R 734	28d	2.9 mo	8.3 mo	7	R 5 141 PFS proxy	17
Apatinib monotherapy Variant #01 Partial	—	—	28d	1.8 mo	5.8 mo	2	—	2
Nivolumab monotherapy Variant #01 Partial	—	—	14d	1.8 mo	5.3 mo	2	—	2
Placebo Partial	—	—	—	0.9 mo	4.0 mo	—	—	6
Irinotecan liposomal monotherapy Variant #01 Partial	—	—	21d	—	—	~2	—	—
Best supportive care Partial	—	—	—	—	3.7 mo	—	—	4

22 of 22 regimens shown